Hartford Business.com
March 16, 2010
Browse News by Topic
- Agriculture
- Architecture
- Banking & Finance
- Biotechnology
- Construction
- Economy
- Education
- Energy
- Government & Politics
- Health Care
- Insurance
- Legal
- Manufacturing
- Media & Marketing
- Nonprofits
- Real Estate
- Restaurant & Food
- Retail
- Small Business
- Technology
- Telecom
- Tourism
- Transportation
Data Products
To Do List
- Subscribe to the HBJ
- Signup for HBJ Today & eNews
- Get In The HBJ (PDF)
- View HBJ Business Profiles
- Get Your Company Listed in the HBJ
- Send Us A Press Release
- Add a Calendar Item
- Advertise in the HBJ
- Register for the CT Business Expo
- Update your account information
- Book Of Lists 2009 Cover Quiz
Awards & Events
- View Supplements Online
- HBJ Events Details
- Health Care Heroes
- Diversity
- Best Places to Work
- eTechnology Summit and Strateg-e Awards
- Women in Business
- CT Business Expo
- Business Champions
- Nonprofit Heroes
- Book of Lists Preview Party
- Business Energy Summit
- 40 Under Forty
- CFO of the Year
- Business Leaders of the Year
- Photo Gallery
Ailing Branford biotech firm CuraGen Corp. announced today the expansion of clinical trials on its treatment for advanced breast cancer, good news for CuraGen's soon-to-be owner.
CuraGen recently agreed to a $95 million buyout by Celldex Therapeutics Inc. of Needham, Mass. The stock transaction will close in the third quarter.
CuraGen said two of the first four eligible patients in the Phase II trial showed enough progress after 12 weeks on its breast cancer treatment to warrant expanded testing to about 25 patients.
Updated study results are expected in the second half of this year, CuraGen said.
This article does not currently have any comments